SMAD2 and non-small cell lung carcinoma: CCT6A has also been shown to suppress decapentaplegic homolog 2 (SMAD2) function in non-small cell lung cancer (NSCLC) cells and to promote metastasis by directly binding to SMAD2 protein, while the selective inhibition of CCT6A efficiently suppresses TGF-β-mediated metastasis [25].